

Additional file 4: Associations significant after correction for multiple testing

Metabolite ^{a, b}	Method	Model	1st quartile	2st quartile	3rd quartile	4th quartile
Overall prostate cancer (40-60 years)						
LPC C17:0	MS	Cut-point (μ M)	≤ 1.30	>1.30 to ≤ 1.57	>1.57 to ≤ 1.89	>1.89
		OR (95% CI)	1.00 (referent)	1.44 (1.07 – 1.96)	1.43 (1.06 – 1.94)	1.63 (1.20 – 2.21)
		P-value	-	0.0178	0.0184	0.0017
		N (cases/controls)	147/195	202/194	202/194	226/194
LPC C18:0	MS	Cut-point (μ M)	≤ 21.6	$21.6 >$ to ≤ 24.7	$24.7 >$ to ≤ 28.9	>28.9
		OR (95% CI)	1.00 (referent)	1.08 (0.81 – 1.45)	1.32 (1.00 – 1.75)	1.36 (1.02 – 1.81)
		P-value	-	0.5947	0.0514	0.0342
		N (cases/controls)	163/195	177/194	216/194	221/194
Overall prostate cancer (40-50 years)						
Glycine	NMR	Cut-point (μ M)	≤ 170.1	$170.1 >$ to ≤ 197.2	$197.2 >$ to ≤ 217.7	>217.7
		OR (95% CI)	1.00 (referent)	1.13 (0.70 – 1.83)	1.12 (0.70 – 1.81)	1.75 (1.09 – 2.82)
		P-value	-	0.6216	0.6316	0.0212
		N (cases/controls)	69/82	73/81	74/82	110/81
Pyruvate	NMR	Cut-point (μ M)	≤ 64.5	$64.5 >$ to ≤ 78.8	$78.8 >$ to ≤ 99.5	>99.5
		OR (95% CI)	1.00 (referent)	0.62 (0.40 – 0.97)	1.04 (0.69 – 1.57)	0.46 (0.29 – 0.74)
		P-value	-	0.0374	0.8673	0.0013
		N (cases/controls)	102/82	70/81	105/82	49/81
Overall prostate cancer (60 years)						
LPC C17:0*	MS	Cut-point (μ M)	≤ 1.26	>1.26 to ≤ 1.53	>1.53 to ≤ 1.84	>1.84
		OR (95% CI)	1.00 (referent)	1.97 (1.29 – 3.01)	2.10 (1.37 – 3.24)	2.56 (1.67 – 3.93)
		P-value	-	0.0016	0.0007	<0.0001
		N (cases/controls)	63/111	116/111	119/111	146/111
LPC C18:0	MS	Cut-point (μ M)	≤ 21.4	$21.4 >$ to ≤ 24.4	$24.4 >$ to ≤ 28.5	>28.5
		OR (95% CI)	1.00 (referent)	0.95 (0.64 – 1.39)	1.30 (0.89 – 1.90)	1.54 (1.07 – 2.22)
		P-value	-	0.7722	0.1820	0.0206
		N (cases/controls)	93/111	87/111	119/111	145/111
Aggressive prostate cancer (40-60 years)						
LPC C17:0	MS	Cut-point (μ M)	≤ 1.26	$1.26 >$ to ≤ 1.53	$1.53 >$ to ≤ 1.85	>1.85
		OR (95% CI)	1.00 (referent)	1.64 (0.80 – 3.38)	2.69 (1.29 – 5.60)	3.35 (1.66 – 6.76)
		P-value	-	0.1719	0.0085	0.0008
		N (cases/controls)	22/43	33/42	50/42	64/42
PC ae C38:3	MS	Cut-point (μ M)	≤ 3.39	$3.39 >$ to ≤ 3.92	$3.92 >$ to ≤ 4.58	>4.58
		OR (95% CI)	1.00 (referent)	1.54 (0.77 – 3.10)	1.98 (0.96 – 4.12)	2.52 (1.28 – 4.97)
		P-value	-	0.2246	0.0665	0.0077
		N (cases/controls)	27/43	37/42	45/42	60/42
PC ae C38:4	MS	Cut-point (μ M)	≤ 9.65	$9.65 >$ to ≤ 11.3	$11.3 >$ to ≤ 13.0	>13.0
		OR (95% CI)	1.00 (referent)	1.32 (0.68 – 2.56)	1.70 (0.85 – 3.39)	2.24 (1.17 – 4.29)
		P-value	-	0.4135	0.1340	0.0147
		N (cases/controls)	29/43	36/42	44/42	60/42

Additional file 4: Continued

Metabolite ^{a, b}	Method	Model	1st quartile	2st quartile	3rd quartile	4th quartile
Aggressive prostate cancer (40-60 years)						
LPC C20:4	MS	Cut-point (μ M)	≤ 3.69	$3.69 > \text{to } \leq 4.43$	$4.43 > \text{to } \leq 5.46$	> 5.46
		OR (95% CI)	1.00 (referent)	1.24 (0.59 – 2.59)	1.98 (0.98 – 4.02)	2.13 (1.08 – 4.23)
		P-value	-	0.5673	0.0569	0.0300
		N (cases/controls)	30/43	32/42	51/42	56/42
LPC C20:3	MS	Cut-point (μ M)	≤ 1.59	$1.59 > \text{to } \leq 1.92$	$1.92 > \text{to } \leq 2.32$	> 2.32
		OR (95% CI)	1.00 (referent)	1.41 (0.76 – 2.61)	1.97 (1.03 – 3.77)	1.83 (0.96 – 3.48)
		P-value	-	0.2828	0.0410	0.0652
		N (cases/controls)	28/43	40/42	52/42	49/42
PC ae C40:2	MS	Cut-point (μ M)	≤ 1.78	$1.78 > \text{to } \leq 2.06$	$2.06 > \text{to } \leq 2.42$	> 2.42
		OR (95% CI)	1.00 (referent)	1.02 (0.54 – 1.94)	1.69 (0.90 – 3.18)	1.85 (1.00 – 3.41)
		P-value	-	0.9413	0.1053	0.0488
		N (cases/controls)	31/43	33/42	50/42	55/42
C18:2	MS	Cut-point (μ M)	≤ 0.035	$0.035 > \text{to } \leq 0.042$	$0.042 > \text{to } \leq 0.051$	> 0.051
		OR (95% CI)	1.00 (referent)	0.80 (0.46 – 1.40)	0.48 (0.25 – 0.92)	0.55 (0.30 – 1.00)
		P-value	-	0.4212	0.0263	0.0494
		N (cases/controls)	60/43	47/42	30/42	32/42
Aggressive prostate cancer (60 years)						
LPC C17:0	MS	Cut-point (μ M)	≤ 1.24	$1.24 > \text{to } \leq 1.52$	$1.52 > \text{to } \leq 1.78$	> 1.78
		OR (95% CI)	1.00 (referent)	1.63 (0.69 – 3.84)	2.17 (0.92 – 5.15)	3.90 (1.70 – 8.99)
		P-value	-	0.2684	0.0776	0.0014
		N (cases/controls)	16/32	25/31	31/31	53/31

^a All metabolites listed were significant after correction for multiple testing (FDR, 20%) based on p_{crude} -values in Additional file 3.

^b Metabolites that were significant after Bonferroni correction based on p_{crude} -values in Additional file 3 are marked with (*).